RXRX

Recursion Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 2/10
  • Momentum↓ 2/10
Recursion Pharmaceuticals sales and earnings growth
RXRX Growth
Fair
  • Revenue Y/Y↓ -32.98%
  • EPS Y/Y↓ -18.71%
  • FCF Y/Y↓ -34.73%
Recursion Pharmaceuticals gross and profit margin trends
RXRX Profitability
Low
  • Gross margin ↓ -59.00%
  • EPS margin↓ -1637.80%
  • ROIC↓ -311.80%
Recursion Pharmaceuticals net debt vs free cash flow
RXRX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Recursion Pharmaceuticals stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗